New Data Demonstrating the Clinical Utility of Daxor’s BVA-100 in Hypertension Management to be Presented at the American H...
November 08 2018 - 1:46PM
Daxor to Exhibit at American Heart
Association 2018
Daxor Corporation
(NYSE MKT: DXR) an investment
company with innovative medical instrumentation and biotechnology
operations focused on blood volume measurement today announces it
will be attending the American Heart Association Scientific
Sessions (AHA) at the McCormick Place Convention Center in Chicago,
IL from November 10-12th, 2018. A presentation by Marat Fudim, M.D.
of Duke University Medical Center demonstrating the clinical
utility of blood volume analysis to help guide hypertension
management will be featured.
“The AHA Annual Meeting is a leading event
gathering over 12,000 experts from around the world focused on
reducing disabilities and death from cardiovascular disease and
stroke. Eighty-five percent of heart failure patients have a known
history of hypertension. We are looking forward to sharing with
leaders in the field how our BVA-100 (Blood Volume Analyzer) has
been proven to not only reduce heart failure 30-day mortality by
82% and 30-day readmissions by 56%, but also how volume management
is an essential component to help guide hypertension therapy. The
Centers for Disease Control and Prevention estimates one in three
adults have hypertension (or high blood pressure), a leading cause
of stroke, heart attack and kidney failure,” said Michael
Feldschuh, CEO of Daxor Corporation. The company will be exhibiting
at Booth #2016.
About Daxor Corporation
Daxor Corporation is an innovative medical
instrumentation and biotechnology company. We manufacture the
BVA-100 Blood Volume Analyzer, the first instrument approved by the
FDA to provide rapid direct measurement of a patient’s blood
volume. We believe that the BVA-100 Blood Volume Analyzer has the
potential to transform therapy in a broad range of surgical and
medical conditions. It is our goal, working in conjunction with
hospitals and clinics, to achieve that possibility. Ultimately the
company’s mission is to help hospitals and physicians incorporate
Daxor’s BVA-100 diagnostic to significantly improve the quality of
patient care. For more information please visit our website at
http://www.daxor.com.
Forward-Looking Statements
Certain statements in this release may include
forward-looking statements within the meaning of the Private
Securities Litigation Reform Act of 1995, including without
limitation, statements regarding the impact of hiring sales staff
and expansion of our distribution channels. Forward-looking
statements are predictions, projections and other statements about
future events that are based on current expectations and
assumptions and, as a result, are subject to risks and
uncertainties. Many factors could cause actual future events to
differ materially from the forward-looking statements in this
release, including, without limitation, those risk associated with
our post-market clinical data collection activities, benefits of
our products to patients, our expectations with respect to product
development and commercialization efforts, our ability to increase
market and physician acceptance of our products, potentially
competitive product offerings, intellectual property protection,
FDA regulatory actions, our ability to integrate acquired
businesses, our expectations regarding anticipated synergies with
and benefits from acquired businesses, and additional other risks
and uncertainties described in our filings with the SEC.
Forward-looking statements speak only as of the date when made.
Daxor does not assume any obligation to publicly update or revise
any forward-looking statements, whether as a result of new
information, future events or otherwise.
Contact Information:
Investor Relations Contact:Bret ShapiroSr. Managing PartnerCORE
IR561-479-8566brets@coreir.com
Daxor (AMEX:DXR)
Historical Stock Chart
From Aug 2024 to Sep 2024
Daxor (AMEX:DXR)
Historical Stock Chart
From Sep 2023 to Sep 2024